Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 14/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134689 | 0.92 | CA12 (0.40) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134926 | 0.87 | HRH3 (0.46) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134286 | 0.86 | HDAC3 (0.40) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134291 | 0.85 | MKNK1 (0.43) | MAPTHRH3 | |
| SCHEMBL6134754 | 0.84 | HRH3 (0.45) | ALDH1A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL6132409 | 0.82 | MAPT (0.41) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6132534 | 0.81 | TP53 (0.50) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6135143 | 0.81 | MAPT (0.42) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134955 | 0.80 | HRH3 (0.41) | MAPTHRH3 | |
| SCHEMBL6135134 | 0.80 | TP53 (0.44) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CA12 3234/4885CA1 2356/4885CA2 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.